Equities research analysts at StockNews.com began coverage on shares of Quotient (NASDAQ:QTNT – Get Rating) in a research report issued to clients and investors on Sunday. The brokerage set a "hold" rating on the stock.
QTNT has been the topic of several other reports. BTIG Research reduced their price objective on Quotient from $9.00 to $1.50 and set a "buy" rating on the stock in a report on Wednesday, June 29th. Cowen reduced their price objective on Quotient from $9.00 to $3.00 and set an "outperform" rating on the stock in a report on Wednesday, June 29th. Finally, Cowen reduced their price objective on Quotient from $9.00 to $3.00 and set an "outperform" rating on the stock in a report on Wednesday, June 29th. Two analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and an average target price of $2.25.
Get
Quotient alerts:
Quotient Price Performance
Shares of QTNT opened at $0.15 on Friday. The company has a market capitalization of $15.77 million, a P/E ratio of -0.11 and a beta of 2.76. Quotient has a one year low of $0.15 and a one year high of $3.19. The business's 50 day simple moving average is $0.22 and its 200-day simple moving average is $0.46.
Quotient (NASDAQ:QTNT – Get Rating) last announced its earnings results on Tuesday, August 9th. The company reported ($0.37) EPS for the quarter, missing the consensus estimate of ($0.28) by ($0.09). The firm had revenue of $8.81 million during the quarter, compared to analyst estimates of $9.40 million. On average, sell-side analysts anticipate that Quotient will post -0.69 EPS for the current fiscal year.
Insiders Place Their Bets
In other news, Director Prondzynski Heino Von bought 700,000 shares of the stock in a transaction on Thursday, September 15th. The stock was purchased at an average price of $0.20 per share, for a total transaction of $140,000.00. Following the acquisition, the director now owns 1,405,879 shares in the company, valued at $281,175.80. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In the last 90 days, insiders bought 984,808 shares of company stock worth $195,354. Corporate insiders own 10.50% of the company's stock.
Hedge Funds Weigh In On Quotient
A number of large investors have recently modified their holdings of the business. Highbridge Capital Management LLC boosted its stake in shares of Quotient by 24.2% during the 1st quarter. Highbridge Capital Management LLC now owns 9,117,257 shares of the company's stock worth $10,941,000 after buying an additional 1,776,154 shares during the last quarter. Clearbridge Investments LLC boosted its stake in shares of Quotient by 0.8% during the 1st quarter. Clearbridge Investments LLC now owns 4,255,908 shares of the company's stock worth $5,107,000 after buying an additional 33,409 shares during the last quarter. JPMorgan Chase & Co. boosted its stake in shares of Quotient by 9,156.7% during the 2nd quarter. JPMorgan Chase & Co. now owns 3,491,154 shares of the company's stock worth $838,000 after buying an additional 3,453,439 shares during the last quarter. Walleye Capital LLC boosted its stake in shares of Quotient by 4,136.3% during the 2nd quarter. Walleye Capital LLC now owns 3,000,000 shares of the company's stock worth $720,000 after buying an additional 2,929,184 shares during the last quarter. Finally, State Street Corp boosted its stake in shares of Quotient by 8.1% during the 1st quarter. State Street Corp now owns 1,502,911 shares of the company's stock worth $1,803,000 after buying an additional 112,013 shares during the last quarter. 86.84% of the stock is currently owned by institutional investors and hedge funds.
Quotient Company Profile
(Get Rating)
Quotient Limited, a commercial-stage diagnostics company, develops, manufactures, commercializes, and sells products for the global transfusion diagnostics market in the United States, France, Japan, and internationally. The company is developing MosaiQ, a proprietary technology platform, which provides tests for immunohematology, serological disease screening, and molecular disease screening.
Featured Stories
- Get a free copy of the StockNews.com research report on Quotient (QTNT)
- Is the Market Overreacting with Shopify Stock?
- MO Money: Why Altria Group Stock is Rallying
- Fed Raises Rates: 3 Stocks to Watch Newmont Mining, Walmart, AMC
- Three Consumer Stocks That Could Outperform In Q4
- Comcast is an Asset Bonanza Priced Cheap
Receive News & Ratings for Quotient Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quotient and related companies with MarketBeat.com's FREE daily email newsletter.
